<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00519571</url>
  </required_header>
  <id_info>
    <org_study_id>IL-01</org_study_id>
    <nct_id>NCT00519571</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Efficacy of Using ImplantLock Device - Dental Implant Accessory</brief_title>
  <official_title>Evaluation of the Safety and Efficacy of Using ImplantLock Device - Dental Implant Accessory</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovative Implant Solutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovative Implant Solutions</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the safety and effectiveness of the ImplantLock device and its contribution to&#xD;
      8.0 mm long root-form endosseous implants stability under immediately applied continuous&#xD;
      functional loading.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Endpoints&#xD;
&#xD;
        -  Serious adverse events occurrence rate (during implantation procedure or following&#xD;
           implantation) related to the ImplantLock device will be documented in Serious Adverse&#xD;
           Event Form.&#xD;
&#xD;
        -  Adverse events occurrence rate (during implantation procedure or following implantation)&#xD;
           related to the ImplantLock device will be documented in Adverse Event Form.&#xD;
&#xD;
      Secondary Endpoints&#xD;
&#xD;
        -  Determine 8.0 mm long endosseous implant stability while using ImplantLock Device.&#xD;
           Stability will be routinely assessed.&#xD;
&#xD;
        -  Determine the ability to immediately apply continuous functional loading on 8.0 mm long&#xD;
           endosseous implant while using ImplantLock Device. The ability to immediately apply&#xD;
           continuous functional loading will be routinely assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">July 2009</completion_date>
  <primary_completion_date type="Anticipated">June 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events and serious adverse events occurrence rate (during implantation procedure or following implantation) related to the ImplantLock device</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine endosseous implant stability while using ImplantLock Device</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the ability to immediately apply continuous functional loading on endosseous implant while using ImplantLock Device</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Dental Implantation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ImplantLock device</intervention_name>
    <description>dental implant</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male/Female age 18 and up.&#xD;
&#xD;
          -  Subject is schedule for endosseous implantation treatment.&#xD;
&#xD;
          -  Subject able to comprehend and give informed consent for participation in this study.&#xD;
&#xD;
          -  Signed informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects suffering from a disease that might disturb bone regeneration healing process&#xD;
             e.g. osteoporosis, anemia, etc.&#xD;
&#xD;
          -  Acute infection requiring intravenous antibiotics at the time of screening.&#xD;
&#xD;
          -  Bleeding disorders.&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus&#xD;
&#xD;
          -  HIV positive or any other immunosuppressive disorder.&#xD;
&#xD;
          -  Renal failure (Serum creatinine &gt;2.0 mg/dl).&#xD;
&#xD;
          -  Subject with allergies to metal alloys.&#xD;
&#xD;
          -  Coagulation disorder.&#xD;
&#xD;
          -  Infection / abscess / pains in treatment target area.&#xD;
&#xD;
          -  Pregnant or nursing woman.&#xD;
&#xD;
          -  Resent history of alcohol or drug abuse (within the last 2 years).&#xD;
&#xD;
          -  Subject is smoking.&#xD;
&#xD;
          -  Subject is suffering extreme general weakness.&#xD;
&#xD;
          -  Subject objects to the study protocol.&#xD;
&#xD;
          -  Known cognitive or psychiatric disorder&#xD;
&#xD;
          -  Concurrent participation in any other clinical study.&#xD;
&#xD;
          -  Physician objection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isaac Tayeb, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Center,Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hanna Levy, Dr</last_name>
    <phone>972-4-638-8837</phone>
    <email>hanna@qsitemed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hadassah Medical center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Hanna Levy, Dr.</last_name>
      <phone>972-4-638-8837</phone>
      <email>hanna@qsitemed.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <study_first_submitted>August 20, 2007</study_first_submitted>
  <study_first_submitted_qc>August 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2007</study_first_posted>
  <last_update_submitted>May 8, 2008</last_update_submitted>
  <last_update_submitted_qc>May 8, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Hanna Levy, Clinical Study Consultant</name_title>
    <organization>IIS Ltd</organization>
  </responsible_party>
  <keyword>Dental Implantation, Endosseous</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

